Egypts pain management market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Pain is caused due to the unpleasant sensory stimulation caused due to damage to the tissues by any means. Although majorly caused by injuries, it is also prevalent in the case of diseases such as arthritis, ulcers, cancer, and multiple sclerosis. Acute pain is generated for a short period, whereas chronic pain is persistent for extended time periods. Several pain management drugs and devices are available in the market that work by blocking the nerve stimulators by transmitting the unpleasant sensory experience to the brain.

The middle east region in particular has the largest market share in the pain management industry due to increasing awareness among the people and increasing chronic diseases.

Few years back WHO reported a shortage of oral morphine in Egypt. This does not appear to have been due to cost, since fentanyl, hydromorphone, and oxycodone were still available. In the absence of oral morphine, these formulations are the only locally available alternative to oral morphine, but they are more expensive and are therefore unaffordable for many cancer patients in Egypt. Therefore, now is a good time to enter the Egyptian pain management market with better alternatives.



Market Drivers

An increase in demand for alternatives to side effects causing pain management drugs, increasing the number of chronic patients especially in the geriatric population of Egypt, and technological advancements in the arena will drive the market.

A rise in patients suffering from cancer and neuropathic diseases will also drive the market for pain management devices.

Major constraint factors are the large side-effects associated with these devices and their high manufacturing costs.